Role of 99mTc-hexakis-2-methoxyisobutylisonitrile in the diagnosis and staging of lung cancer

Mario Nosotti, Luigi Santambrogio, Massimo Gasparini, Alessandro Baisi, Nadia Bellaviti, Lorenzo Rosso

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Background: Preliminary studies have shown that 99mTc-hexakis-2-methoxyisobutylisonitrile (MIBI) is an interesting tracer for various tumors. The aim of this study was to determine the feasibility of using 99mTc-MIBI as a diagnostic and staging procedure for lung cancer. Methods: We prospectively compared the results of biopsy with 99mTc-MIBI imaging in patients with potentially resectable lung lesions (stages IIIA or lower). In the patients with radiopharmaceutical uptake, the staging provided by CT was compared with that obtained with 99mTc-MIBI. Results: Ninety-nine of the 116 patients examined had lung cancer. For the diagnosis of malignancy, the specificity of 99mTc-MIBI was 100%, sensitivity was 89.8%, positive predictive value was 100%, negative predictive value was 62.9%, and accuracy was 91.4%. In the 87 patients with radiopharmaceutical uptake in their lung cancer, the values for the specificity and sensitivity of 99mTc-MIBI in the detection of mediastinal lymph node metastases were 100% and 54.5%, respectively. The corresponding values for CT in the same patients were 87.6% and 63.3%, respectively. The difference in specificity is statistically significant (p = 0.011). Conclusions: This study demonstrates that 99mTc-MIBI provides significant diagnostic and staging information in patients with lung lesions. The high specificity and positive predictive value of 99mTc-MIBI suggest that this radiopharmaceutical could be a very useful tool for the diagnosis of lung cancer, especially in consideration of its low costs and wide availability.

Original languageEnglish
Pages (from-to)1361-1364
Number of pages4
JournalChest
Volume122
Issue number4
DOIs
Publication statusPublished - 2002

Fingerprint

Lung Neoplasms
Radiopharmaceuticals
Lung
technetium 99m methoxyisobutylisonitrile
2-methoxyisobutylisonitrile
Neoplasms
Lymph Nodes
Neoplasm Metastasis
Biopsy
Costs and Cost Analysis
Sensitivity and Specificity

Keywords

  • Tc-hexakis-2-methoxyisobutylisonitrile
  • Lung cancer
  • Staging

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Role of 99mTc-hexakis-2-methoxyisobutylisonitrile in the diagnosis and staging of lung cancer. / Nosotti, Mario; Santambrogio, Luigi; Gasparini, Massimo; Baisi, Alessandro; Bellaviti, Nadia; Rosso, Lorenzo.

In: Chest, Vol. 122, No. 4, 2002, p. 1361-1364.

Research output: Contribution to journalArticle

@article{0b56a93874734ac29d7926a30dac71cf,
title = "Role of 99mTc-hexakis-2-methoxyisobutylisonitrile in the diagnosis and staging of lung cancer",
abstract = "Background: Preliminary studies have shown that 99mTc-hexakis-2-methoxyisobutylisonitrile (MIBI) is an interesting tracer for various tumors. The aim of this study was to determine the feasibility of using 99mTc-MIBI as a diagnostic and staging procedure for lung cancer. Methods: We prospectively compared the results of biopsy with 99mTc-MIBI imaging in patients with potentially resectable lung lesions (stages IIIA or lower). In the patients with radiopharmaceutical uptake, the staging provided by CT was compared with that obtained with 99mTc-MIBI. Results: Ninety-nine of the 116 patients examined had lung cancer. For the diagnosis of malignancy, the specificity of 99mTc-MIBI was 100{\%}, sensitivity was 89.8{\%}, positive predictive value was 100{\%}, negative predictive value was 62.9{\%}, and accuracy was 91.4{\%}. In the 87 patients with radiopharmaceutical uptake in their lung cancer, the values for the specificity and sensitivity of 99mTc-MIBI in the detection of mediastinal lymph node metastases were 100{\%} and 54.5{\%}, respectively. The corresponding values for CT in the same patients were 87.6{\%} and 63.3{\%}, respectively. The difference in specificity is statistically significant (p = 0.011). Conclusions: This study demonstrates that 99mTc-MIBI provides significant diagnostic and staging information in patients with lung lesions. The high specificity and positive predictive value of 99mTc-MIBI suggest that this radiopharmaceutical could be a very useful tool for the diagnosis of lung cancer, especially in consideration of its low costs and wide availability.",
keywords = "Tc-hexakis-2-methoxyisobutylisonitrile, Lung cancer, Staging",
author = "Mario Nosotti and Luigi Santambrogio and Massimo Gasparini and Alessandro Baisi and Nadia Bellaviti and Lorenzo Rosso",
year = "2002",
doi = "10.1378/chest.122.4.1361",
language = "English",
volume = "122",
pages = "1361--1364",
journal = "Chest",
issn = "0012-3692",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Role of 99mTc-hexakis-2-methoxyisobutylisonitrile in the diagnosis and staging of lung cancer

AU - Nosotti, Mario

AU - Santambrogio, Luigi

AU - Gasparini, Massimo

AU - Baisi, Alessandro

AU - Bellaviti, Nadia

AU - Rosso, Lorenzo

PY - 2002

Y1 - 2002

N2 - Background: Preliminary studies have shown that 99mTc-hexakis-2-methoxyisobutylisonitrile (MIBI) is an interesting tracer for various tumors. The aim of this study was to determine the feasibility of using 99mTc-MIBI as a diagnostic and staging procedure for lung cancer. Methods: We prospectively compared the results of biopsy with 99mTc-MIBI imaging in patients with potentially resectable lung lesions (stages IIIA or lower). In the patients with radiopharmaceutical uptake, the staging provided by CT was compared with that obtained with 99mTc-MIBI. Results: Ninety-nine of the 116 patients examined had lung cancer. For the diagnosis of malignancy, the specificity of 99mTc-MIBI was 100%, sensitivity was 89.8%, positive predictive value was 100%, negative predictive value was 62.9%, and accuracy was 91.4%. In the 87 patients with radiopharmaceutical uptake in their lung cancer, the values for the specificity and sensitivity of 99mTc-MIBI in the detection of mediastinal lymph node metastases were 100% and 54.5%, respectively. The corresponding values for CT in the same patients were 87.6% and 63.3%, respectively. The difference in specificity is statistically significant (p = 0.011). Conclusions: This study demonstrates that 99mTc-MIBI provides significant diagnostic and staging information in patients with lung lesions. The high specificity and positive predictive value of 99mTc-MIBI suggest that this radiopharmaceutical could be a very useful tool for the diagnosis of lung cancer, especially in consideration of its low costs and wide availability.

AB - Background: Preliminary studies have shown that 99mTc-hexakis-2-methoxyisobutylisonitrile (MIBI) is an interesting tracer for various tumors. The aim of this study was to determine the feasibility of using 99mTc-MIBI as a diagnostic and staging procedure for lung cancer. Methods: We prospectively compared the results of biopsy with 99mTc-MIBI imaging in patients with potentially resectable lung lesions (stages IIIA or lower). In the patients with radiopharmaceutical uptake, the staging provided by CT was compared with that obtained with 99mTc-MIBI. Results: Ninety-nine of the 116 patients examined had lung cancer. For the diagnosis of malignancy, the specificity of 99mTc-MIBI was 100%, sensitivity was 89.8%, positive predictive value was 100%, negative predictive value was 62.9%, and accuracy was 91.4%. In the 87 patients with radiopharmaceutical uptake in their lung cancer, the values for the specificity and sensitivity of 99mTc-MIBI in the detection of mediastinal lymph node metastases were 100% and 54.5%, respectively. The corresponding values for CT in the same patients were 87.6% and 63.3%, respectively. The difference in specificity is statistically significant (p = 0.011). Conclusions: This study demonstrates that 99mTc-MIBI provides significant diagnostic and staging information in patients with lung lesions. The high specificity and positive predictive value of 99mTc-MIBI suggest that this radiopharmaceutical could be a very useful tool for the diagnosis of lung cancer, especially in consideration of its low costs and wide availability.

KW - Tc-hexakis-2-methoxyisobutylisonitrile

KW - Lung cancer

KW - Staging

UR - http://www.scopus.com/inward/record.url?scp=0036428944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036428944&partnerID=8YFLogxK

U2 - 10.1378/chest.122.4.1361

DO - 10.1378/chest.122.4.1361

M3 - Article

C2 - 12377865

AN - SCOPUS:0036428944

VL - 122

SP - 1361

EP - 1364

JO - Chest

JF - Chest

SN - 0012-3692

IS - 4

ER -